within Pharmacolibrary.Drugs.ATC.A;

model A10BJ05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.47,
    Cl             = 0.114 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0192,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dulaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. It improves glycemic control by enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Dulaglutide is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult type 2 diabetic patients, following repeated subcutaneous administration. Parameters reflect pooled values from both sexes across multiple doses. Population PK analysis, mainly in adults aged 18-75, various ethnic groups.</p><h4>References</h4><ol><li><p>Pratley, RE, et al., &amp; Viljoen, A (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. <i>The lancet. Diabetes &amp; endocrinology</i> 6(4) 275–286. DOI:<a href=&quot;https://doi.org/10.1016/S2213-8587(18)30024-X&quot;>10.1016/S2213-8587(18)30024-X</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29397376/&quot;>https://pubmed.ncbi.nlm.nih.gov/29397376</a></p></li><li><p>Bucheit, JD, et al., &amp; Sisson, EM (2020). Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. <i>Diabetes technology &amp; therapeutics</i> 22(1) 10–18. DOI:<a href=&quot;https://doi.org/10.1089/dia.2019.0185&quot;>10.1089/dia.2019.0185</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31436480/&quot;>https://pubmed.ncbi.nlm.nih.gov/31436480</a></p></li><li><p>Urva, S, et al., &amp; Milicevic, Z (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. <i>Lancet (London, England)</i> 400(10366) 1869–1881. DOI:<a href=&quot;https://doi.org/10.1016/S0140-6736(22)02033-5&quot;>10.1016/S0140-6736(22)02033-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36354040/&quot;>https://pubmed.ncbi.nlm.nih.gov/36354040</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BJ05;
